argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
1,028.51
-3.15 (-0.31%)
Sep 1, 2026, 4:00 PM EDT - Market closed
argenx SE Employees
argenx SE had 1,863 employees as of December 31, 2025. The number of employees increased by 264 or 16.51% compared to the previous year.
Employees
1,863
Change (1Y)
264
Growth (1Y)
16.51%
Revenue / Employee
$2,853,177
Profits / Employee
$920,577
Market Cap
64.25B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,863 | 264 | 16.51% |
| Dec 31, 2024 | 1,599 | 451 | 39.29% |
| Dec 31, 2023 | 1,148 | 305 | 36.18% |
| Dec 31, 2022 | 843 | 193 | 29.69% |
| Dec 31, 2021 | 650 | 314 | 93.45% |
| Dec 31, 2020 | 336 | 148 | 78.72% |
| Dec 31, 2019 | 188 | 83 | 79.05% |
| Dec 31, 2018 | 105 | 32 | 43.84% |
| Dec 31, 2017 | 73 | 15 | 25.86% |
| Dec 31, 2016 | 58 | 17 | 41.46% |
| Dec 31, 2015 | 41 | 9 | 28.13% |
| Dec 31, 2014 | 32 | 10 | 45.45% |
| Dec 31, 2013 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
ARGX News
- 3 hours ago - Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? - The Motley Fool
- 1 day ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 1 day ago - ARGX Maintained by Morgan Stanley -- Price Target Raised to $1250 - GuruFocus
- 2 days ago - Argenx price target raised to $1,250 from $1,230 at Morgan Stanley - TheFly
- 5 days ago - argenx Completes Acquisition of Forte Biosciences, Inc. - GlobeNewsWire
- 6 days ago - ARGX Upgraded by UBS -- Price Target Raised to $1400 - GuruFocus
- 6 days ago - ARGX Looks 29.0% Undervalued on GF Value⢠- GuruFocus
- 6 days ago - ARGX Maintains Rating by Wells Fargo -- Price Target Raised to $1415 - GuruFocus